Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OTTx peptide candidate (neuropathic pain)
- Development stage
- Preclinical
- Lead developer
- On Target Therapeutics
- Modality
- Peptides
01
Overview
OTTx peptide candidate (neuropathic pain) is a preclinical-stage, long-acting peptide modulator developed by On Target Therapeutics. The drug is designed to target an unspecified G protein-coupled receptor (GPCR) involved in pain signaling. By utilizing the company's platform for creating stable peptide modulators, the candidate aims to provide a durable therapeutic effect for the treatment of neuropathic pain. The program is currently in the preclinical phase, with the developer seeking industry partners for further clinical development and co-development into Phase I or Phase II trials.
Beyond the preview
Go deeper on OTTx peptide candidate (neuropathic pain).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OTTx peptide candidate (neuropathic pain).